In this context of penta‐refractory (bortezomib, lenalidomide, carfilzomib, pomalidomide, and daratumumab) MM with extramedullary BRAF‐mutated disease, the combination of dabrafenib (an oral BRAF inhibitor) associated with trametinib (an oral MEK inhibitor) was initiated. Here, MAP2K7 is linked to Miyoshi myopathy.